Here are the 10-Q quarterly reports from Teva Pharm Indus Ltd (TEVJF) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow TEVJF and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full TEVJF filings page.
Teva Pharmaceutical Industries Limited reported Q2 2026 net revenues of $4,142 million, roughly flat versus $4,176 million a year earlier, but recorded a net loss attributable to Teva of $576 million, compared with net income of $282 million. The loss reflects sharply higher R&D expense of $970 million, including a $724 million in‑process R&D charge from the Emalex Biosciences acquisition, and $230 million of legal settlements and loss contingencies.
For the first six months of 2026, net revenues were $8,124 million and net loss attributable to Teva was $207 million. Operating cash flow was $371 million, while investing activities used $263 million, largely driven by Emalex. At June 30 2026, cash and cash equivalents were $3,655 million, total assets $39,857 million, total equity $7,757 million, short‑term debt $4,500 million and long‑term senior notes and loans $12,092 million. Teva continues to classify its API business as held for sale, with $1,794 million of related assets and $313 million of liabilities, and maintains a $4,854 million provision for legal settlements and loss contingencies related to ongoing matters.
Teva Pharmaceutical Industries reported Q3 2025 results showing higher profitability. Net revenues were $4,480 million, up from $4,332 million a year ago. Operating income reached $882 million versus a loss last year, and net income attributable to Teva was $433 million (basic EPS $0.38; diluted $0.37). For the first nine months, net revenues were $12,547 million with net income of $930 million.
The balance sheet reflects $2,203 million in cash and cash equivalents, total assets of $39,856 million, and Teva shareholders’ equity of $7,250 million. Senior notes and loans were $16,766 million. Teva executed several 2025 note repayments and, in May 2025, issued new senior notes of $700 million (5.75% due 2030), €1,000 million (4.125% due 2031) and $500 million (6.00% due 2032). A June 2025 tender extinguished multiple tranches, resulting in a $10 million loss recorded in financial expenses. Shares outstanding were 1,147,282,512 as of September 30, 2025.